MedTrace Logo

The Comparison Between the Biomarkers in Inflammatory Bowel Disease Patients and General Control Group

NCT03778918 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-03-03

No results posted yet for this study

Summary

The aims of this study is to investigate a blood-based biomarker that can replace endoscopy in patients with inflammatory bowel disease. For this purpose, blood sample of patients wiht inflammatory bowel disease (ulcerative colitis, Crohn 's disease) was collected at the same time the endoscopy is performed, stored after centrifugation, and analyzed accordingly. Selected biomarkers from the blood sample were investigated to compare those of patients with inflammatory bowel disease and those of general controls. Males and females over the age of 19 participated in the study and are excluded if they have chronic kidney disease or blood clotting disease. The outcome is a find of a blood-based biomarker that best reflects a disease activity.

Conditions

  • Inflammatory Bowel Diseases
  • Irritable Bowel Syndrome

Interventions

OTHER

inflammatory bowel disease

blood based biomarkers in IBD such as REG3 alpha, serum calprotectin and hs-CRP

OTHER

IBS or Normal Control

blood based biomarker compared normal control with IBD

Sponsors & Collaborators

  • Incheon St.Mary's Hospital

    collaborator OTHER

  • St Vincent's Hospital

    collaborator OTHER

  • Daejeon St. Mary's hospital

    collaborator OTHER

  • Bo-In Lee

    lead OTHER

Principal Investigators

  • Bo-In Lee, MD. Ph.D. · Seoul St. Mary's Hospital

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-01
Primary Completion
2020-06-30
Completion
2020-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03778918 on ClinicalTrials.gov